Stockscreener 앱 받기
2.10
0.96%
0.02
전일 마감가:
$2.08
열려 있는:
$2.08
하루 거래량:
213.20K
Relative Volume:
0.43
시가총액:
$144.82M
수익:
$8.38M
순이익/손실:
$-27.19M
주가수익비율:
-1.9266
EPS:
-1.09
순현금흐름:
$-13.59M
1주 성능:
+8.81%
1개월 성능:
-1.87%
6개월 성능:
+87.50%
1년 성능:
+81.03%
1일 변동 폭
$2.03
$2.15
1주일 범위
$1.88
$2.2551
52주 변동 폭
$0.65
$2.5907
Opus Genetics Inc Stock (IRD) Company Profile
명칭
Opus Genetics Inc
전화
248-681-9815
주소
8 DAVIS DRIVE, DURHAM
IRD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
2.10 | 143.45M | 8.38M | -27.19M | -13.59M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-10 | 개시 | B. Riley Securities | Buy |
| 2025-11-25 | 개시 | Piper Sandler | Overweight |
| 2025-10-29 | 개시 | Wedbush | Outperform |
| 2025-10-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-11 | 개시 | Craig Hallum | Buy |
| 2024-11-13 | 재개 | H.C. Wainwright | Buy |
모두보기
Opus Genetics Inc 주식(IRD)의 최신 뉴스
JPM26: Opus Genetics builds momentum in rare retinal gene therapy - Yahoo Finance
Opus Genetics, Inc. Announces Presentation at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit - Clinical Leader
Opus Genetics highlights 2025 progress, upcoming 2026 catalysts - Yahoo Finance
How Opus Genetics Inc. stock reacts to oil pricesWeekly Profit Report & Risk Controlled Daily Trade Plans - Улправда
Merger Talk: How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivalsTrade Risk Summary & Free Accurate Trade Setup Notifications - Улправда
How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivals2025 Momentum Check & Community Verified Watchlist Alerts - Улправда
Earnings Risk: Is Opus Genetics Inc. stock attractive for growth ETFsPortfolio Performance Summary & Free Community Supported Trade Ideas - Улправда
How interest rate cuts could boost Opus Genetics Inc. stock2025 Major Catalysts & Weekly Stock Performance Updates - Улправда
Opus Genetics (IRD) Advances Clinical Trials and Regulatory Fili - GuruFocus
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - The Manila Times
Opus Genetics Details 2025 Progress and 2026 Milestones - TipRanks
Opus Genetics Highlights 2025 Progress and 2026 Catalysts - TradingView — Track All Markets
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - Defense World
Independent Chairman of Opus Genetics Picks Up 9.5% More Stock - simplywall.st
Caprolactam Chemicals Limited Stock Analysis Technical Signals for YEAR - earlytimes.in
What drives Opus Genetics Inc stock priceEx-Dividend Date Alerts & Small Investment Portfolio - earlytimes.in
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Bridgewater Associates, AQR Capital Management, Schonfeld Strategic Advisors, D.E. Shaw, Millennium Management, Elliott Management, Discovery Capital Management, Opus Genetics Inc - Insider Monkey
Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update - MSN
Portfolio Shifts: How Opus Genetics Inc stock performs in stagflationWeekly Market Outlook & Low Risk High Reward Trade Ideas - moha.gov.vn
Opus Genetics (NASDAQ:IRD) Director Cam Gallagher Purchases 83,000 Shares - MarketBeat
Shorts Report: Why Opus Genetics Inc R3X1 stock is upgraded to buy - moha.gov.vn
B Riley Securities initiates coverage of Opus Genetics (IRD) with buy recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Soaring Eagle Acquisition Corp Equity Warrant Stock Analysis and ForecastLong-Term Growth Stocks & Superior Capital Appreciation - earlytimes.in
Opus Genetics Inc R3X1 Stock Analysis and ForecastMarket Insider Reports & Discover Strategies with Fellow Traders - earlytimes.in
MACD Signals Flash Warning for Compucom Software Limited StockMACD Trading Signals & Minimal Investment Big Returns - earlytimes.in
Opus Genetics rises as eye disease study to proceed without changes - MSN
Rate Hike: Why Opus Genetics Inc stock could benefit from AI revolutionInsider Selling & Proven Capital Preservation Tips - moha.gov.vn
Will Opus Genetics Inc. stock outperform growth indexesProfit Target & Consistent Growth Equity Picks - Улправда
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Will Opus Genetics Inc. stock gain from lower inflationMarket Growth Summary & Low Risk Profit Maximizing Plans - Улправда
Opus Genetics partner files supplemental NDA for presbyopia drug - MSN
Why Opus Genetics Inc. stock is a value investor pick2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Bank Watch: Is Opus Genetics Inc. stock attractive for growth ETFsMarket Volume Summary & Daily Risk Controlled Trade Plans - DonanımHaber
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics Earnings Notes - Trefis
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
Insider Selling: Opus Genetics (NASDAQ:IRD) Director Sells 4,000,000 Shares of Stock - MarketBeat
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) By Investing.com - Investing.com South Africa
Opus Genetics (IRD) Price Target Increased by 13.45% to 7.87 - MSN
Foundation Fighting Blindness Retinal Degeneration Fund Sells 4,000,000 Shares of Opus Genetics Inc (IRD) - GuruFocus
Foundation fighting blindness sells $8.6 million in Opus Genetics (IRD) - Investing.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference | Associated Press | syndication news - Enidnews.com
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference - marketscreener.com
Opus Genetics Inc (IRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Opus Genetics Inc 주식 (IRD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gallagher Cam | Director |
Dec 29 '25 |
Buy |
1.98 |
81,000 |
160,275 |
1,891,430 |
| Foundation Fighting Blindness | Director |
Dec 09 '25 |
Sale |
2.15 |
4,000,000 |
8,600,000 |
5,492,171 |
4.73%
0.92%
자본화:
|
볼륨(24시간):